As of May 26
| +1.60 / +4.69%|
The 6 analysts offering 12-month price forecasts for Supernus Pharmaceuticals Inc have a median target of 35.50, with a high estimate of 45.00 and a low estimate of 30.00. The median estimate represents a -0.70% decrease from the last price of 35.75.
The current consensus among 6 polled investment analysts is to Buy stock in Supernus Pharmaceuticals Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.